Issues of biocompatibility: Heparin-coated extracorporeal circuit

International Anesthesiology Clinics

Volumn 34, Issue 2, 1996, Pages 109-122

  Hsu, Li Chien ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULATION; BIOCOMPATIBILITY; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; EXTRACORPOREAL OXYGENATION; HEPARINIZATION; OPEN HEART SURGERY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION;

EID: 0029946201     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-199603420-00010     Document Type: Review

References (58)

1. Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954;37:171-185
2. Chenoweth DE, Copper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503
3. Hashimoto K, Miyamoto H, Suzuki K, et al. Evidence of organ damage after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104:666-673
4. Kirkin JK. The post perfusion syndrome: inflammation and the damaging effects of cardiopulmonary bypass. In: John Tinker, ed. Cardiopulmonary Bypass Current Concepts and Controversies. Monograph. Philadelphia: W. B. Saunders, 1989: 131-146
5. Preissner KT. Physiological role of vessel wall related antithrombotic mechanisms: contribution of endogenous and exogenous heparin-like components to the anticoagulant potential of the endothelium. Hemostasis 1990;20(Suppl 1):30-49
6. Downing SW, Edmunds LH Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236-1243
7. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993;56:S92-S96
8. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45
9. Bell WR. Heparin-associated thrombocytopenia and thrombosis. J Lab Clin Med 1988;111:600-605
10. Bidstrup BP, Royston D, Sapsford RN, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-372
11. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-553
12. van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-797
13. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106:1-10
14. Arom KV, Emery RW. Decreased postoperative drainage with addition of aminocaproic acid before cardiopulmonary bypass. Ann Thorac Surg 1994;57:1108-1113
15. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. J Thorac Cardiovasc Surg 1995;110: 835-842
16. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54:1031-1038
17. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-1041
18. van Oeveren W, Kazatchkine MD, Descamps-Latscha B, et al. Deleterious effects of cardiopulmonary bypass: a prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985;89:888-899
19. Blauth C, Smith PL, Arnold JV, et al. Influence of oxygenator type on the incidence and extent of microembolic retinal ischemia during cardiopulmonary bypass. Assessment by digital image analysis. J Thorac Cardiovasc Surg 1990;99:61-69
20. van Oeveren W, Dankert J, Wildevuur ChRH. Bubble oxygenation and cardiotomy suction impair the host defense during cardiopulmonary bypass. A study in dogs. Ann Thorac Surg 1987;44:523-528
21. Videm V, Fosse E, Mollnes TE, et al. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting. Ann Thorac Surg 1990; 50:387-391
22. Hessel EA, Johnson DD, Ivey TD, et al. Membrane versus bubble oxygenator for cardiac operations. A prospective randomized study. J Thorac Cardiovasc Surg 1980;80:111-122
23. Schonberger JPAM, Everts PAM, Hoffmann JJ. Systemic blood activation with open and closed venous reservoirs. Ann Thorac Surg 1995;59:1549-1555
24. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-857
25. Gervin AS, Manson K, Limbird, et al. Ultrapore filter-induced thrombocytopenia. Surgery 1974;75:566-572
26. Heimbecker R, Rober A, McKenzie FN. The extracorporeal pump filter - saint or sinner? Ann Thorac Surg 1976;21:55-58
27. Longmore DB, Bennet G, Gueirrara D, et al. Prostacyclin: a solution to some problems of extracorporeal circulation. Lancet 1979;1:1002-1005
28. Hsu LC, Loar ME, Tong SD. Thromboresistant properties of surface modified arterial filter materials. Trans Soc Biomater 1991;14:112
29. Borowiec JW, Bylock A, van der Linden J, et al. Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study. Ann Thorac Surg 1993;55:1540-1545
30. Loos M, Volanakis JE, Stroud RM. Mode of interaction of different polyanions with the first, the second, and the fourth component of complement II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry 1976;13:257-261
31. Kazatchkine MD, Fearon DT, Metcalfe DD, et al. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification of C3 convertase. J Clin Invest 1981;67:223-228
32. Gravlee GP. Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesthesia 1994;8:213-222
33. Larm O, Larsson R, Olsson P. A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Dev Artif Organs 1983;11:161-163
34. Hsu LC. Heparin coating of bypass circuits: principles of heparin-coating techniques. Perfusion 1991;6:209-219
35. Nojiri C, Hagiwara K, Yokoyama K, et al. Evaluation of a new heparin bonding process in prolonged extracorporeal membrane oxygenation. ASAIO Journal 1995; 41:M561-M567
36. Wendel HP, Heller W, Hoffmeister HE. Pathway of platelet protection in heparincoated devices and its significance for cardiovascular surgery. Trans Soc Biomater 1995;21:281
37. Reynolds L, Clark R, Drumm G. In-vitro efficacy test for arterial filter materials. Trans Soc Biomater 1985;11:115
38. Tong SD, Rolfs MR, Hsu LC. Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits. ASAIO Journal 1990;36:654-656
39. Hsu LC. Duraflo II heparin-treated extracorporeal devices. Proc Am Acad Cardiovasc Perfusion 1992;13:135-139
40. Toomasian JM, Hsu LC, Hirschl RB, et al. Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. ASAIO Journal 1988;34: 410-414
41. von Segesser LK, Turinus M. Cardiopulmonary bypass without systemic heparin. J Thorac Cardiovasc Surg 1989;98:386-396
42. von Segesser LK, Turina M. Long-term cardiopulmonary bypass without systemic heparinization. Int J Artif Organs 1990;13:687-691
43. Tong SD, Hsu LC. Non-thrombogenic hemofiltration system for acute renal failure treatment. ASAIO Journal 1992;38:M702-M706
44. Gu YJ, van Oeveren W, van der Kamp KWHJ, et al. Heparin coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991;6:221-225
45. Pradhan MJ, Fleming JS, Nkere UU, et al. Clinical experience with heparin coated cardiopulmonary bypass circuits. Perfusion 1991;6:235-242
46. Nakajima T, Ogawa M, Sasaki T, et al. Clinical study of coagulofibrinolytic system and platelet function with Duraflo II coated cardiopulmonary bypass equipment. ASAIO Journal 1994;23:61 Abstract
47. Gravlee GP, Phipps J, Mills SA, et al. Hematologic evaluation of a heparin-coated circuit for cardiopulmonary bypass. Anesthesiology 1992;77:A99
48. Del Balza UH, Levi R, Policy MJ. Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Nat Acad Sci 1985;82:886-890
49. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86;845-857
50. Gu YJ, van Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55: 917-922
51. Jansen PGM, te Velthuis H, Huybregts RAJM, et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin coated circuits. J Thorac Cardiovasc Surg 1995;110:829-834
52. Jansen PGM. Stepwise reduction in pathophysiologic aspects of cardiopulmonary bypass. PhD thesis, Amsterdam: Free University, 1995
53. von Segesser LK, Weiss BM, Pasic M, et al. Risk and benefit of low systemic heparinization during open heart operation. Ann Thorac Surg 1994;58:391-398
54. Penka M, Hagman L, Halden E, et al. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994;58:421-424
55. Ovrum E, Holen EA, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995;60:365-371
56. Ovrum E, Brosstad F, Holen EA, et al. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995;92:2579-2584
57. von Segesser LK, Weiss BM, von Felton E, et al. Perfusion without systemic heparinization for rewarming in accidental deep hypothermia. Ann Thorac Surg 1991;52: 560-561
58. von Segesser LK, Tkebuchava T, Leskosek B, et al. Low prime, heparin-coated centrifugal pump. Perfusion 1995;10:177-182